Skip to content
Search

Latest Stories

Moonpig share price up on debut on the London Stock Exchange

Moonpig share price up on debut on the London Stock Exchange

MOONPIG, the online greeting cards group that has seen sales surge during pandemic lockdowns, debuted on Tuesday (2) on the London Stock Exchange with a valuation of £1.2 billion.

It quickly shot above the valuation level as its offer price of 350 pence per share reached 440 pence at the start of trading reserved for institutional investors. Full trading begins on Friday (5).


Moonpig, bought in 2016 by British private equity group Exponent, has floated 41 per cent of the business.

"Listing on the London Stock Exchange is an incredibly special milestone and will provide new opportunities for the business," Moonpig chief executive Nickyl Raithatha said in a statement.

"As the leaders of a market undergoing an accelerating shift to online, now is the perfect time for us to bring the company to the public market, and we are excited about Moonpig's prospects."

British app-driven meals delivery service Deliveroo is planning to list later this year.

"We can expect more announcements like this from UK companies this year as we see UK Tech come into its own, which has particular importance in a post-Brexit world," Stephen Kelly, chair of consultants Tech Nation, said in a statement Tuesday.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less